HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Monopar Therapeutics in a research report issued to clients and investors on Monday, September 29th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.26) for the year, up from their previous estimate of ($1.34). HC Wainwright currently has a “Buy” rating and a $105.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2028 earnings at ($0.37) EPS and FY2029 earnings at $0.28 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.

A number of other analysts have also recently issued reports on MNPR. Piper Sandler set a $95.00 target price on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Raymond James Financial assumed coverage on shares of Monopar Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Oppenheimer started coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $77.00 price target for the company. Finally, BTIG Research raised their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics currently has an average rating of “Buy” and an average price target of $86.22.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $84.73 on Wednesday. The business has a 50 day simple moving average of $46.54 and a 200 day simple moving average of $40.42. Monopar Therapeutics has a 52 week low of $4.50 and a 52 week high of $85.58. The stock has a market cap of $522.78 million, a price-to-earnings ratio of -25.44 and a beta of 1.41.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. AlphaQuest LLC boosted its stake in Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after buying an additional 569 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at about $34,000. JPMorgan Chase & Co. boosted its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics in the second quarter valued at about $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the second quarter worth about $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Chandler Robinson sold 16,800 shares of the company’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares in the company, valued at $2,938,880. The trade was a 18.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company’s stock, valued at $206,920. This represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 592,733 shares of company stock valued at $36,700,227. Corporate insiders own 20.50% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.